Sangamo Therapeutics

Sangamo BioSciences is a biotechnology company focused on translating science into genomic therapies using its platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company is engaged in research and development of zinc finger proteins (ZFPs), a naturally occurring class of proteins found in humans. ZFPs can be engineered to make zinc finger nucleases, proteins that can be used to specifically modify Deoxyribonucleic acid sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors, proteins that can be used to increase or decrease gene expression, or gene regulation.
  • TickerSGMO
  • ISINUS8006771062
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Aug 15

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Aug 15

Liana Moussatos ...
  • Shveta Dighe

Q2 Financials; SB-525/Hemophilia A and ST-400 Beta-thalassemia Data In Q4

2 directors bought/sold after exercising options

Two Directors at Sangamo Therapeutics Inc bought/sold after exercising options 7,000 shares at between 13.520USD and 14.169USD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading a...

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

ValuEngine Rating and Forecast Report for SGMO

MarketLine Department

Ionis Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Ionis Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Ionis Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competi...

MarketLine Department

Sangamo BioSciences, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Summary Pharmaceuticals and Healthcare Key Findings Pharmaceuticals and Healthcare Pharmaceuticals and Healthcare Reasons To Buys MarketLine Key Highlights United States

Dave Nicoski ...
  • John Betz

Vermilion Compass: Weekly Equity Strategy

• Bullish but selective. As we alluded to last week, our long-term bullish outlook remains intact. However, looking through the charts we find a growing list of extended and parabolic patterns. While we continue to remain bullish, we acknowledge the likelihood of backing and filling, or a pause, is building. The further a stock's price action moves from its 200-day, the greater the possibility of a corrective reversion to the mean, or pullback. In last week's Compass our example was Boeing Corporation (BA). The stock is trading 40% above its 200-day moving average, and this rate of momentum i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch